Prognostic factors for local control after breast conservation: Does margin status still matter?

Journal of Clinical Oncology

Volumn 27, Issue 30, 2009, Pages 4929-4930

  MacDonald, Shannon ^a   Taghian, Alphonse G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL RESEARCH; CONSERVATIVE TREATMENT; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SYSTEMIC THERAPY;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 77649147223     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6679     Document Type: Editorial

References (19)

1. Jones HA, Antonini N, Hart AAM, et al: Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC Boost Versus No Boost Trial. J Clin Oncol 27:4940-4948, 2009
2. Fisher B, Anderson S, Bryant J, et al: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002
3. Veronesi U, Cascinelli N, Mariani L, et al: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232, 2002
4. Bartelink H, Horiot JC, Poortmans P, et al: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378-1387, 2001
5. Bartelink H, Horiot JC, Poortmans PM, et al: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25:3259-3265, 2007
6. Poortmans P, Bartelink H, Horiot JC, et al: The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial. Radiother Oncol 72:25-33, 2004
7. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378, 2008
8. Kyndi M, Sorensen FB, Knudsen H, et al: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419-1426, 2008
9. Jobsen JJ, van der Palen J, Ong F, et al: The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys 57:724-731, 2003
10. Romestaing P, Lehingue Y, Carrie C, et al: Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963-968, 1997
11. Anscher MS, Jones P, Prosnitz LR, et al: Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg 218:22-28, 1993
12. Mansfield CM, Komarnicky LT, Schwartz GF, et al: Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer 75:2328-2336, 1995
13. Smitt MC, Nowels KW, Zdeblick MJ, et al: The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 76:259-267, 1995
14. DiBiase SJ, Komarnicky LT, Schwartz GF, et al: The number of positive margins influences the outcome of women treated with breast preservation for early stage breast carcinoma. Cancer 82:2212-2220, 1998
15. Wazer DE, Schmidt-Ullrich RK, Ruthazer R, et al: Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiat Oncol Biol Phys 40:851-858, 1998
16. Park CC, Mitsumori M, Nixon A, et al: Outcome at 8 years after breastconserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18:1668-1675, 2000
17. Kreike B, Hart AA, van de Velde T, et al: Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. Int J Radiat Oncol Biol Phys 71:1014-1021, 2008
18. Poortmans PM, Collette L, Horiot JC, et al: Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol 90:80-85, 2009
19. Taghian A, Mohiuddin M, Jagsi R, et al: Current perceptions regarding surgical margin status after breast-conserving therapy: Results of a survey. Ann Surg 241:629-639, 2005